<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04377763</url>
  </required_header>
  <id_info>
    <org_study_id>20MWI-SEROCOV</org_study_id>
    <nct_id>NCT04377763</nct_id>
  </id_info>
  <brief_title>Developement and Evaluation of Serological Assays for COVID-19</brief_title>
  <acronym>SEROCOV</acronym>
  <official_title>Developement and Evaluation of Serological Assays for COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study aims to evaluate serological assays of virus Covid-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective monocentric study, which will include the patients who have
      hospitalized in Ambroise Paré Hospital and have sampling sent to the Laboratory of
      Microbiology of the hospital between the 15 March 2020 and 30 september 2020.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensibility and specificity</measure>
    <time_frame>Throughout of the study, an average of 6 months</time_frame>
    <description>Determination of sensibility and specificity of serological testing in SARS-CoV-2 virus in patients with acute respiratory symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delay between the first symptoms and the positive serological result</measure>
    <time_frame>Throughout of the study, an average of 6 months</time_frame>
    <description>Delay between the first symptoms and the positive serological result of SARS-CoV-2 virus.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>COVID-19</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with positive or negative molecular diagnosis of Covid-19, in the Laboratory
        of Microbiology of Ambroise Paré Hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient ≥ 18 years;

          -  Have molecular diagnosis of positive or negative result in Covid-19 virus by the
             Laboratory of Microbiology in Ambroise Paré Hospital;

          -  Have diagnosed of a viral infection in respiratory.

        Exclusion Criteria:

        - Patient refusal.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Anne RAMEIX-WELTI, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laboratoire de Microbiologie Hygiène hospitalière, Hôpital Ambroise paré, APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Anne RAMEIX-WELTI, MD, PhD</last_name>
    <phone>+33 (0)6 65 13 64 34</phone>
    <email>marie-anne.welti@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Laboratory of microbiology of hospital hygiene, Ambroise Paré Hospital, APHP</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>serological assay</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

